FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
© 2022. The Author(s)..
Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting enzyme 2 (ACE2)1, could represent a new chemoprophylactic approach for COVID-19 that complements vaccination2,3. However, the mechanisms that control the expression of ACE2 remain unclear. Here we show that the farnesoid X receptor (FXR) is a direct regulator of ACE2 transcription in several tissues affected by COVID-19, including the gastrointestinal and respiratory systems. We then use the over-the-counter compound z-guggulsterone and the off-patent drug ursodeoxycholic acid (UDCA) to reduce FXR signalling and downregulate ACE2 in human lung, cholangiocyte and intestinal organoids and in the corresponding tissues in mice and hamsters. We show that the UDCA-mediated downregulation of ACE2 reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ. Furthermore, we reveal that UDCA reduces the expression of ACE2 in the nasal epithelium in humans. Finally, we identify a correlation between UDCA treatment and positive clinical outcomes after SARS-CoV-2 infection using retrospective registry data, and confirm these findings in an independent validation cohort of recipients of liver transplants. In conclusion, we show that FXR has a role in controlling ACE2 expression and provide evidence that modulation of this pathway could be beneficial for reducing SARS-CoV-2 infection, paving the way for future clinical trials.
| Errataetall: |
CommentIn: Nat Rev Drug Discov. 2023 Feb;22(2):97. - PMID 36517581 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:615 |
|---|---|
| Enthalten in: |
Nature - 615(2023), 7950 vom: 01. März, Seite 134-142 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.03.2023 Date Revised 21.11.2023 published: Print-Electronic CommentIn: Nat Rev Drug Discov. 2023 Feb;22(2):97. - PMID 36517581 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41586-022-05594-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349827885 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349827885 | ||
| 003 | DE-627 | ||
| 005 | 20231226043548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41586-022-05594-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM349827885 | ||
| 035 | |a (NLM)36470304 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brevini, Teresa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2023 | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Nat Rev Drug Discov. 2023 Feb;22(2):97. - PMID 36517581 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting enzyme 2 (ACE2)1, could represent a new chemoprophylactic approach for COVID-19 that complements vaccination2,3. However, the mechanisms that control the expression of ACE2 remain unclear. Here we show that the farnesoid X receptor (FXR) is a direct regulator of ACE2 transcription in several tissues affected by COVID-19, including the gastrointestinal and respiratory systems. We then use the over-the-counter compound z-guggulsterone and the off-patent drug ursodeoxycholic acid (UDCA) to reduce FXR signalling and downregulate ACE2 in human lung, cholangiocyte and intestinal organoids and in the corresponding tissues in mice and hamsters. We show that the UDCA-mediated downregulation of ACE2 reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ. Furthermore, we reveal that UDCA reduces the expression of ACE2 in the nasal epithelium in humans. Finally, we identify a correlation between UDCA treatment and positive clinical outcomes after SARS-CoV-2 infection using retrospective registry data, and confirm these findings in an independent validation cohort of recipients of liver transplants. In conclusion, we show that FXR has a role in controlling ACE2 expression and provide evidence that modulation of this pathway could be beneficial for reducing SARS-CoV-2 infection, paving the way for future clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Receptors, Virus |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a farnesoid X-activated receptor |2 NLM | |
| 650 | 7 | |a 0C5V0MRU6P |2 NLM | |
| 650 | 7 | |a pregna-4,17-diene-3,16-dione |2 NLM | |
| 650 | 7 | |a A4PW148END |2 NLM | |
| 650 | 7 | |a Ursodeoxycholic Acid |2 NLM | |
| 650 | 7 | |a 724L30Y2QR |2 NLM | |
| 700 | 1 | |a Maes, Mailis |e verfasserin |4 aut | |
| 700 | 1 | |a Webb, Gwilym J |e verfasserin |4 aut | |
| 700 | 1 | |a John, Binu V |e verfasserin |4 aut | |
| 700 | 1 | |a Fuchs, Claudia D |e verfasserin |4 aut | |
| 700 | 1 | |a Buescher, Gustav |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Griffiths, Chelsea |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Marnie L |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, William E |c 3rd |e verfasserin |4 aut | |
| 700 | 1 | |a Pereyra-Gerber, Pehuén |e verfasserin |4 aut | |
| 700 | 1 | |a Gelson, William T H |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Dillon, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Muraro, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Sharp, Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Neary, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Box, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Tatham, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, James |e verfasserin |4 aut | |
| 700 | 1 | |a Curley, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Pertinez, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Forrest, Sally |e verfasserin |4 aut | |
| 700 | 1 | |a Mlcochova, Petra |e verfasserin |4 aut | |
| 700 | 1 | |a Varankar, Sagar S |e verfasserin |4 aut | |
| 700 | 1 | |a Darvish-Damavandi, Mahnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Mulcahy, Victoria L |e verfasserin |4 aut | |
| 700 | 1 | |a Kuc, Rhoda E |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Thomas L |e verfasserin |4 aut | |
| 700 | 1 | |a Heslop, James A |e verfasserin |4 aut | |
| 700 | 1 | |a Rossetti, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Tysoe, Olivia C |e verfasserin |4 aut | |
| 700 | 1 | |a Galanakis, Vasileios |e verfasserin |4 aut | |
| 700 | 1 | |a Vila-Gonzalez, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Crozier, Thomas W M |e verfasserin |4 aut | |
| 700 | 1 | |a Bargehr, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Upponi, Sara S |e verfasserin |4 aut | |
| 700 | 1 | |a Fear, Corrina |e verfasserin |4 aut | |
| 700 | 1 | |a Swift, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Saeb-Parsy, Kourosh |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Susan E |e verfasserin |4 aut | |
| 700 | 1 | |a Wester, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Hagström, Hannes |e verfasserin |4 aut | |
| 700 | 1 | |a Melum, Espen |e verfasserin |4 aut | |
| 700 | 1 | |a Clements, Darran |e verfasserin |4 aut | |
| 700 | 1 | |a Humphreys, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Herriott, Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Kijak, Edyta |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Bramwell, Chloe |e verfasserin |4 aut | |
| 700 | 1 | |a Valentijn, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Illingworth, Christopher J R |e verfasserin |4 aut | |
| 700 | 0 | |a UK-PBC Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Dahman, Bassam |e verfasserin |4 aut | |
| 700 | 1 | |a Bastaich, Dustin R |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Raphaella D |e verfasserin |4 aut | |
| 700 | 1 | |a Marjot, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, Eleanor |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Andrew M |e verfasserin |4 aut | |
| 700 | 1 | |a Barritt, Alfred S |c 4th |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ravindra K |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Davenport, Anthony P |e verfasserin |4 aut | |
| 700 | 1 | |a Corbett, Gareth |e verfasserin |4 aut | |
| 700 | 1 | |a Gorgoulis, Vassilis G |e verfasserin |4 aut | |
| 700 | 1 | |a Buczacki, Simon J A |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Joo-Hyeon |e verfasserin |4 aut | |
| 700 | 1 | |a Matheson, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Trauner, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Fisher, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbs, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Christopher J E |e verfasserin |4 aut | |
| 700 | 1 | |a Mells, George F |e verfasserin |4 aut | |
| 700 | 1 | |a Dougan, Gordon |e verfasserin |4 aut | |
| 700 | 1 | |a Owen, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Lohse, Ansgar W |e verfasserin |4 aut | |
| 700 | 1 | |a Vallier, Ludovic |e verfasserin |4 aut | |
| 700 | 1 | |a Sampaziotis, Fotios |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature |d 1945 |g 615(2023), 7950 vom: 01. März, Seite 134-142 |w (DE-627)NLM000008257 |x 1476-4687 |7 nnns |
| 773 | 1 | 8 | |g volume:615 |g year:2023 |g number:7950 |g day:01 |g month:03 |g pages:134-142 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41586-022-05594-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 615 |j 2023 |e 7950 |b 01 |c 03 |h 134-142 | ||